Dr sc. Muriel Brengues
Dr. Muriel Brengues is a leading expert in ionizing radiation and personalized oncology, currently serving as the Scientific Manager of the Experimental Radiotherapy Platform at the Institut de Recherche en Cancérologie de Montpellier (IRCM / ICM Val d’Aurelle). She is also the Chief Scientific Officer of NovaGray, a medical technology company specializing in predictive blood tests for radiotherapy side effects. Dr. Brengues holds a PhD in Biochemistry, Molecular and Cellular Biology. Prior to her current roles in France, she spent a decade in the United States conducting advanced research within the University of Arizona's Medicine and Applied NanoBioscience departments. Her research focuses on radiosensitivity, experimental irradiation models, and translating preclinical findings into personalized cancer treatments.
Professional profile links: